Immuneering Corp
Clinical-stage oncology firm using bioinformatics to develop oral MEK inhibitors for solid tumors.
IMRX | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 245 MAIN STREET, SECOND FLOOR, 2142 CAMBRIDGE
- Website:
- https://immuneering.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Immuneering Corporation is a clinical-stage oncology company dedicated to developing novel medicines for cancer patients. The company utilizes bioinformatics and computational biology to guide its drug discovery and development pipeline. Its lead product candidate is atebimetinib (IMM-1-104), an oral, once-daily deep cyclic inhibitor of the MEK pathway. This candidate is engineered for improved tolerability and is being evaluated in clinical trials for patients with advanced solid tumors, including pancreatic cancer, with the goal of helping patients outlive their disease.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Immuneering Corp filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Immuneering Corp
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Immuneering Corp via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
